Search Results - "Gatell, Jose"

Beyond viral suppression of HIV - the new quality of life frontier by Lazarus, Jeffrey V, Safreed-Harmon, Kelly, Barton, Simon E, Costagliola, Dominique, Dedes, Nikos, Del Amo Valero, Julia, Gatell, Jose M, Baptista-Leite, Ricardo, Mendão, Luís, Porter, Kholoud, Vella, Stefano, Rockstroh, Jürgen Kurt

“…In 2016, the World Health Organization (WHO) adopted a new Global Health Sector Strategy on HIV for 2016-2021. It establishes 15 ambitious targets, including…”
Get full text

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial by Cahn, Pedro, Dr, Andrade-Villanueva, Jaime, MD, Arribas, José R, MD, Gatell, José M, MD, Lama, Javier R, MD, Norton, Michael, MD, Patterson, Patricia, MD, Madero, Juan Sierra, MD, Sued, Omar, MD, Figueroa, Maria Inés, MD, Rolon, Maria José, MD

“…Summary Background Daily oral triple therapy is effective at halting HIV disease progression, but can have toxic effects and is costly. We investigated whether…”
Get full text

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial by Raffi, François, Prof, Jaeger, Hans, MD, Quiros-Roldan, Eugenia, MD, Albrecht, Helmut, Prof, Belonosova, Elena, MD, Gatell, Jose M, Prof, Baril, Jean-Guy, MD, Domingo, Pere, MD, Brennan, Clare, DPT, Almond, Steve, MMath, Min, Sherene, MD

“…Summary Background In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in…”
Get full text

HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications by Blanco, Jose-Luis, Varghese, Vici, Rhee, Soo-Yon, Gatell, Jose M., Shafer, Robert W.

“…With the approval in 2007 of the first integrase inhibitor (INI), raltegravir, clinicians became better able to suppress virus replication in patients infected…”
Get full text

Differential microRNA expression profile between stimulated PBMCs from HIV-1 infected elite controllers and viremic progressors by Egaña-Gorroño, Lander, Escribà, Tuixent, Boulanger, Nicolas, Guardo, Alberto Crespo, León, Agathe, Bargalló, Manel Enric, Garcia, Felipe, Gatell, José María, Plana, Montserrat, Arnedo, Mireia

“…The emerging relationship between microRNAs (miRNA) and viral-control is a topic of interest in the field of HIV. Host-genome might play an important role in…”
Get full text

Tolerability of integrase inhibitors in a real-life setting by Peñafiel, Judit, de Lazzari, Elisa, Padilla, Mireia, Rojas, Jhon, Gonzalez-Cordon, Ana, Blanco, Jose L, Blanch, Jordi, Marcos, Maria A, Lonca, Montserrat, Martinez-Rebollar, Maria, Laguno, Montserrat, Tricas, Amparo, Rodriguez, Ana, Mallolas, Josep, Gatell, Jose M, Martinez, Esteban

“…Integrase inhibitors have shown better tolerability than other drugs in clinical trials, but some post-marketing data have suggested potential differences…”
Get full text

Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers by Barroso, Sergio, Morén, Constanza, González-Segura, Àlex, Riba, Neus, Arnaiz, Joan A, Manriquez, Marcela, Santana, Gemina, Blanco, José L, Larousse, María, Loncà, Montse, Lazzari, Elisa de, Llopis, Jaume, Mallolas, Josep, Miró, Oscar, Carné, Xavier, Gatell, Jose M, Garrabou, Glòria, Martínez, Esteban

“…Classical antiretroviral agents may acutely impact on metabolic, mitochondrial, renal and hepatic function in HIV-infected and uninfected persons. Fusion and…”
Get full text

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial by Grinsztejn, Beatriz, MD, Nguyen, Bach-Yen, Dr, Katlama, Christine, Prof, Gatell, Jose M, Prof, Lazzarin, Adriano, Prof, Vittecoq, Daniel, Prof, Gonzalez, Charles J, MD, Chen, Joshua, PhD, Harvey, Charlotte M, BS, Isaacs, Robin D, MD

“…Summary Background Raltegravir (MK-0518) is an HIV-1 integrase inhibitor with potent in-vitro activity against HIV-1 strains including those resistant to…”
Get full text

Trends in Transmission of Drug Resistance and Prevalence of Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection in Barcelona in the Last 16 Years (1997-2012) by Ambrosioni, Juan, Sued, Omar, Nicolas, David, Parera, Marta, López-Diéguez, María, Romero, Anabel, Agüero, Fernando, Marcos, María Ángeles, Manzardo, Christian, Zamora, Laura, Gómez-Carrillo, Manuel, Gatell, José María, Pumarola, Tomás, Miró, José María

“…To evaluate the prevalence of transmitted drug resistance (TDR) and non-B subtypes in patients with acute/recent HIV-1 infection in Barcelona during the period…”
Get full text

Rate and predictors of progression in elite and viremic HIV-1 controllers by Leon, Agathe, Perez, Ignacio, Ruiz-Mateos, Ezequiel, Benito, Jose Miguel, Leal, Manuel, Lopez-Galindez, Cecilio, Rallon, Norma, Alcami, Jose, Lopez-Aldeguer, Jose, Viciana, Pompeyo, Rodriguez, Carmen, Grau, Eulalia, Iribarren, Jose, Gatell, Jose Maria, Garcia, Felipe

“…BACKGROUND:The proportion of HIV controllers developing virologic, immunological or clinical progression and the baseline predictors of these outcomes have not…”
Get full text

Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant by Beltran-Pavez, Carolina, Ferreira, Carolina B, Merino-Mansilla, Alberto, Fabra-Garcia, Amanda, Casadella, Maria, Noguera-Julian, Marc, Paredes, Roger, Olvera, Alex, Haro, Isabel, Brander, Christian, Garcia, Felipe, Gatell, Jose M, Yuste, Eloisa, Sanchez-Merino, Victor

“…Preventive HIV-1 vaccine strategies rely on the elicitation of broadly neutralizing antibody (bNAb) responses, but their induction in vivo by vaccination…”
Get full text

Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease by Casadellà, Maria, Manzardo, Christian, Noguera-Julian, Marc, Ferrer, Elena, Domingo, Pere, Pérez-Álvarez, Susana, Podzamczer, Daniel, Plana, Montserrat, Clotet, Bonaventura, Gatell, José M, Miró, José M, Paredes, Roger

“…This article aims to investigate if the detection of preexisting drug-resistant minority variant (DRMV) and/or X4 HIV-1 variants could improve the efficacy of…”
Get full text

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial by Blanco, Jose L, Rojas, Jhon, Paredes, Roger, Negredo, Eugenia, Mallolas, Josep, Casadella, Maria, Clotet, Bonaventura, Gatell, Jose M, de Lazzari, Elisa, Martinez, Esteban

“…Abstract Background No controlled comparisons between dolutegravir/lamivudine or dolutegravir maintenance therapy have been done. We hypothesized that these…”
Get full text

The HIV/AIDS Vaccine Candidate MVA-B Administered as a Single Immunogen in Humans Triggers Robust, Polyfunctional, and Selective Effector Memory T Cell Responses to HIV-1 Antigens by GOMEZ, Carmen Elena, NAJERA, José Luis, GUARDO, Alberto C, GARCIA, Felipe, GATELL, Jose M, PLANA, Montserrat, ESTEBAN, Mariano, PERDIGUERO, Beatriz, GARCIA-ARRIAZA, Juan, SORZANO, Carlos Oscar S, JIMENEZ, Victoria, GONZALEZ-SANZ, Rubén, JIMENEZ, José Luis, MUNOZ-FERNANDEZ, Maria Angeles, LOPEZ BERNALDO DE QUIROS, Juan Carlos

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Loading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses by Climent, Núria, García, Isabel, Marradi, Marco, Chiodo, Fabrizio, Miralles, Laia, Maleno, María José, Gatell, José María, García, Felipe, Penadés, Soledad, Plana, Montserrat

“…Gold nanoparticles (GNPs) decorated with glycans ameliorate dendritic cells (DC) uptake, antigen-presentation and T-cells cross-talk, which are important…”
Get full text

Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society–USA Panel by Hammer, Scott M, Eron, Joseph J, Reiss, Peter, Schooley, Robert T, Thompson, Melanie A, Walmsley, Sharon, Cahn, Pedro, Fischl, Margaret A, Gatell, Jose M, Hirsch, Martin S, Jacobsen, Donna M, Montaner, Julio S. G, Richman, Douglas D, Yeni, Patrick G, Volberding, Paul A

“…CONTEXT The availability of new antiretroviral drugs and formulations, including drugs in new classes, and recent data on treatment choices for…”
Get full text

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials by Eron, Joseph J, Prof, Cooper, David A, Prof, Steigbigel, Roy T, Prof, Clotet, Bonaventura, MD, Gatell, Jose M, Prof, Kumar, Princy N, Prof, Rockstroh, Jurgen K, Prof, Schechter, Mauro, Prof, Markowitz, Martin, Prof, Yeni, Patrick, MD, Loutfy, Mona R, MD, Lazzarin, Adriano, Prof, Lennox, Jeffrey L, Prof, Strohmaier, Kim M, BS, Wan, Hong, MS, Barnard, Richard JO, PhD, Nguyen, Bach-Yen T, MD, Teppler, Hedy, MD

“…Summary Background Two randomised, placebo-controlled trials—BENCHMRK-1 and BENCHMRK-2—investigated the efficacy and safety of raltegravir, an HIV-1 integrase…”
Get full text

Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine by de Lazzari, Elisa, Negredo, Eugenia B, Domingo, Pere, Tiraboschi, Juan M, Ribera, Esteve, Abdulghani, Nadia, Alba, Verònica, Fernández-Arroyo, Salvador, Viladés, Consuelo, Peraire, Joaquim, Gatell, Jose M, Blanco, Jose L, Vidal, Francesc, Rull, Anna, Martinez, Esteban

“…The DOLAM trial revealed that switching from triple antiretroviral therapy (three-drug regimen; 3DR) to dolutegravir plus lamivudine (two-drug regimen; 2DR)…”
Get full text

Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials by Steigbigel, Roy T., Cooper, David A., Teppler, Hedy, Eron, Joseph J., Gatell, Jose M., Kumar, Princy N., Rockstroh, Jurgen K., Schechter, Mauro, Katlama, Christine, Markowitz, Martin, Yeni, Patrick, Loutfy, Mona R., Lazzarin, Adriano, Lennox, Jeffrey L., Clotet, Bonaventura, Zhao, Jing, Wan, Hong, Rhodes, Rand R., Strohmaier, Kim M., Barnard, Richard J., Isaacs, Robin D., Nguyen, Bach-Yen T.

“…BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class…”
Get full text

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection by Steigbigel, Roy T, Cooper, David A, Kumar, Princy N, Eron, Joseph E, Schechter, Mauro, Markowitz, Martin, Loutfy, Mona R, Lennox, Jeffrey L, Gatell, Jose M, Rockstroh, Jurgen K, Katlama, Christine, Yeni, Patrick, Lazzarin, Adriano, Clotet, Bonaventura, Zhao, Jing, Chen, Joshua, Ryan, Desmond M, Rhodes, Rand R, Killar, John A, Gilde, Lucinda R, Strohmaier, Kim M, Meibohm, Anne R, Miller, Michael D, Hazuda, Daria J, Nessly, Michael L, DiNubile, Mark J, Isaacs, Robin D, Nguyen, Bach-Yen, Teppler, Hedy

“…For patients infected with multidrug-resistant human immunodeficiency virus type 1 (HIV-1), therapeutic options are limited. Raltegravir is a new molecule that…”
Get full text